Treatment of herpes simplex virus infections with topical antiviral agents

European Journal of Dermatology

Volumn 8, Issue 5, 1998, Pages 310-319

  Hamuy, Ronnit ^a   Berman, Brian ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; ASCORBIC ACID; CAFFEINE; CIDOFOVIR; DIMETHYL SULFOXIDE; IDOXURIDINE; NONOXINOL 9; PENCICLOVIR; TRIFLURIDINE;

CREAM; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG SENSITIVITY; GENE THERAPY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; REVIEW; SKIN PENETRATION; TOPICAL DRUG ADMINISTRATION; VACCINATION; VIRUS SHEDDING;

ADMINISTRATION, TOPICAL; ANTIVIRAL AGENTS; HERPES SIMPLEX; HUMANS;

EID: 0031874012     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Oliver L, Wald A, Kim M, et al. Seroprevalence of Herpes simplex virus infections in a family medicine clinic. Arch Fam Med 1995; 4: 228-32.
2. Sacks S, Aoki F, Diaz-Mitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. J Am Med Assoc 1996; 276: 44-9.
3. Raab B, Lorincz A. Continuing medical education: genital Herpes simplex-concepts and treatment. J Am Acad Dermatol 1981; 5: 249-60.
4. Lawee D, Rosenthal D, Aoki F, et al. Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study. Can Med Assoc J 1988; 138: 329-33.
5. Gold D, Corey L. Acyclovir prophylaxis for Herpes simplex virus infection. Antimicrob Agents Chemother 1987; 31: 361-7.
6. Spruance S, Freeman D. Topical treatment of cutaneous Herpes simplex virus infections. Antiviral Research 1990; 14: 305-21.
7. Gordon H. Glutaraldehyde in treating Herpes simplex and Herpes zoster. Arch Dermatol 1976; 112: 1178.
8. Sery TW, Furgiuele FP. The inactivation of Herpes simplex virus by chemical agents. Am J Ophthalmol 1961; 51: 42-57.
9. Friedrich E, Masakuwa T. Effect on povidone-iodine on herpes genitalis. Obstetrics and Gynecology 1975; 45: 337-9.
10. Freeman D, Wenerstrom G, Spruance S. Treatment of recurrent Herpes simplex labialis with topical butylated hydroxytoluene. Clin Pharmacol Ther 1985; 38: 56-9.
11. Corey L, Reeves W, Chiang WT, et al. Ineffectiveness of topical ether for the treatment of genital Herpes simplex virus infection. N Eng J Med 1978; 299: 237-9.
12. Hovi T, Hirvimies A, Stenvik M, et al. Topical treatment of recurrent mucocutaneous herpes with ascorbic acid-containing solution. Antiviral Research 1995; 27: 263-70.
13. Katzung B. Basic and Clinical Pharmacology. E. Norwalk: Appleton and Lange, 1995.
14. Balfour H, Benson C, Braun J, et al. Management of acyclovir-resistant Herpes simplex and varicella-zoster virus infections. J AIDS 1994; 7: 254-60.
15. Corey L, Nahmias A, Guinan M, et al. A trial of topical acyclovir in genital Herpes simplex virus infections. N Eng J Med 1982; 306: 1313-9.
16. Spruance SL, Schnipper LE, Overall JC, et al. Treatment of Herpes simplex labialis with topical acyclovir in polyethylene glycol. JID 1982; 146: 85-90.
17. Spruance SL, Crumpacker CS, Schnipper LE, et al. Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir. Antimicrob Agents Chemother 1984; 25: 553-5.
18. Fiddian AP, Ivanyi L. Topical acycloir in the management of recurrent herpes labialis. Br J Dermatol 1983; 109: 321-6.
19. Raborn GW, McGaw WT, Grace M, et al. Herpes labialis treatment with acyclovir 5% modified aqueous cream: a double-blind, randomized trial. Oral Surgery 1989; 67: 675-9.
20. Schinazi R. Drug combinations for treatment of mice infected with acyclovir-resistant Herpes simplex virus. Antimicrob Agents and Chemother 1987; 31: 477-9.
21. Schwartz J, Ostrander M, Butkiewicz NJ, et al. Activity of (+)-cyclaradine (Sch 31172) against Herpes simplex virus in vitro and in vivo. Antimicrob Agents Chemother 1987; 31: 21-6.
22. Chatis M, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with Herpes simplex virus in a patient with acquired immune deficiency syndrome. New England J Med 1989, 320: 297-300.
23. Adams H, Benson E, Alexander ER, et al. Genital herpetic infection in men and women: clinical course and effect of topical application of adenine arabinoside. JID 1976; 133 (suppl.): A151-9.
24. Rowe NH, Brooks SL, Young SK, et al. A clinical trial of topically applied 3 percent vidarabine against recurrent herpes labialis. Oral Surgery 1979; 47: 142-7.
25. Spruance SL, Crumpacker CS, Haines H, et al. Ineffectiveness of topical adenine arabinoside 5‰-monophoshate in the treatment of recurrent Herpes simplex labialis. New Engl J Med 1979; 300: 1180-4.
26. Sacks S, Tyrrell L, Lawee D, et al. Randomized, double-blind, placebo-controlled, clinic-initiated, Canadian multicenter trial of topical edoxudine 3.0% cream in the treatment of recurrent genital herpes. JID 1991; 164: 665-72.
27. Snoeck R, Andrei G, Gerard M, et al. ? Clin Infect Dis 1994; 18: 570-8.
28. Mac Callum FO, Juel-Jensen BE. Herpes simplex virus skin infection in a man treated with idoxuridine in dimethyl sulphoxide. Results of double-blind controlled trial. Br Med J 1966; 2: 805-7.
29. Spruance S, Stewart J, Freeman D, et al. Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of Herpes simplex labialis: a multicenter placebo-controlled trial. JID 1990; 161: 191-7.
30. Birch C, Tyssen D, Tachedjan G, et al. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive Herpes simplex virus infections. JID 1992; 166: 108-12.
31. Spruance S, Rea T, Thoming C, et al. Penciclovir cream for the treatment of Herpes simplex labialis. JAMA 1997; 277: 1374-9.
32. Douglas J, Judson F, Levin M, et al. A placebo-controlled trial of topical 8% arildone cream early in recurrent genital herpes. Antimicrob Agents Chemother 1986; 29: 464-7.
33. Janeway C, Travers P. Immunobiology: the immune system in health and disease. Third ed. NY: Garland Publishing, 1997.
34. Shupack J, Stiller M, Knobler E, et al. Topical alpha-interferon in recurrent genital Herpes simplex infection: a double-blind, placebo-controlled clinical trial. Dermatologica 1990; 181: 134-8.
35. Lebwohl M, Sacks S, Conant M, et al. Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis. Antiviral Research 1992; 17: 235-43.
36. Shupack J, Stiller M, Davis I, et al. Topical alpha-interferon ointment with dimethyl sulfoxide in the treatment or recurrent genital Herpes simplex. Dermatology 1992; 184: 40-4.
37. Vonka V, Petrovska P, Borecky L, et al. Increased effects of topically applied interferon in Herpes simplex virus-induced lesions by caffeine. Acta Virologica 1995; 39: 125-30.
38. Isacsohn M, Berson B, Sternberg I, et al. Human fibroblast interferon in treatment of viral diseases of the skin and mucous membranes. Israel J Med Sciences 1983; 19: 959-62.
39. Glezerman M, Cohen V, Movshovitz M, et al. Placebo-controlled trial of topical interferon in labial and genital herpes. Lancet 1988; i: 150-2.
40. Safrin S, Schacker T, Delehanty J, et al. Topical treatment of infection with acyclovir-resistant mucocutaneous Herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir. Antimicrob Agents Chemother 1993; 37: 975-9.
41. Safrin S, McKinley G, McKeough M, et al. Treatment of acyclovir-unresponsive cutaneous Herpes simplex virus infection with topically applied SP-303. Antiviral Research 1994; 25: 185-92.
42. Wallin J, Lernestedt J, Ogenstad S, et al. Topical treatment of recurrent genital herpes infections with foscarnet. Scand J Infect Dis 1985; 17: 165-72.
43. Barton S, Munday P, Kinghorn G, et al. Topical treatment of recurrent genital Herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. Genitourin Med 1986; 62: 247-50.
44. Bryson Y. Promising new antiviral drugs. J Am Acad Dermatol 1988; 18: 212-6.
45. Hellgren L, Hermann LS. Tromantadine hydrochloride in the treatment of Herpes simplex. Results of a double-blind therapeutic trial and open prophylactic investigation. Dermatological 1983; 167: 267-72.
46. Ostheimer KE, Busch T, Gortelmeyer R, Hahn KD. Randomized double-blind trial of tromantadine versus acyclovir in recurrent herpes orofacialis. Arneimittelforsch Drug Res 1989; 39: Heft 9.
47. Petersen C, Weismann K, Avnstorp C, et al. Topical tromatadine in the treatment of genital herpes: a double-blind placebo study. Danish Medical Bulletin 1993; 40: 506-7.
48. Kinghorn G. Topical acyclovir in the treatment of recurrent Herpes simplex virus infections. Scand J Infect Dis 1985; 47 (suppl.): 58-62.
49. Baker E, Hadgraft J. In vitro percutaneous absorption of arildone, a highly lipophilic drug, and the apparent no-effect of the penetration enhancer Azone in excised human skin. Pharmaceutical Research 1995; 12: 993-7.
50. Aboudy Y, Mendelson E, Shalit I, et al. Activity of two synthetic amphiphilic peptides and magainin-2 against Herpes simplex virus types 1 and 2. Internatl J Peptide Protein Research 1994; 43: 573-82.
51. De Maria A, Tundo P, Romano A, et al. Anti-HSV-1 herpes vaccination by Lupidon H: preliminary results. Advances in Experimental Medicine and Biology 1995; 371B: 1599-600.
52. Wong KK, Chatterjee S. Controlling Herpes simplex virus infections: is intracellular immunization the way of the future? Curr Topics Micro Immuno 1992; 170: 159-74.